---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086344"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:08:01.099450+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cryoport Q2 net loss $78M including $63.8M goodwill impairment; FY24 guidance cut to $225-235M

## Summary
- Revenue $57.6M (+1% YoY, +5.5% sequentially); Life Sciences Services up 8%, Products down 10%.
- GAAP EPS loss $1.62 (diluted); Adjusted EBITDA negative $3.8M vs. negative $1.3M a year ago.
- Recorded $63.8M impairment charge related to MVE Biological Solutions goodwill write-off.
- FY 2024 revenue guidance revised to $225-235M from prior range; expects positive adjusted EBITDA in 2025.
- Announced $200M stock/note repurchase program; repurchased $160M of 2026 convertible notes for $141.6M.

## SEC filing metadata
- accession: 0001104659-24-086344
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465924086344/0001104659-24-086344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465924086344/tm2421008d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086344
- JSON: https://secwatch.observer/filing/0001104659-24-086344.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.